A structured synopsis built through dialogue with AI
You describe your idea, the AI ally asks the right questions, reviews the literature, and drafts the key sections of the synopsis — not a form to fill in, a guided conversation.
How it works
From the first sentence to a bilingual synopsis
- 1
Describe your idea
Disease area, target population, research question — a few sentences are enough. The AI takes over on the methodological details.
- 2
Automatic literature review
PubMed, ClinicalTrials.gov and HAL are queried in the background to frame the state of the art and surface ongoing similar trials.
- 3
Synopsis generated, EN + FR
Scientific rationale, objectives, endpoints, inferred methodology: 23 sections drafted and exportable as .docx, ready to share with your research office.
What you get
The framing work, done with you
State of the art in minutes
Pivotal articles, recent meta-analyses, similar ClinicalTrials studies — the review that used to take days is delivered with sources.
One question = one endpoint
The AI enforces objective/endpoint coupling and flags inconsistencies between sections before the methodologist points them out.
Methodology inferred and justified
Study type, randomisation, blinding, comparator: the AI suggests a design consistent with your question — you keep the final word.
Bilingual Word export
Structured .docx aligned with ICH-GCP standards, FR and EN versions generated in parallel for international submissions.
Frequently asked questions
What investigators ask us most
Does the synopsis replace the methodologist's work?
No. The tool produces a serious draft from your question, but the final design validation remains with the methodologist and the research office. You walk into the meeting with a structured document instead of a blank page.
Are my data confidential?
Yes. Hosted in France, GDPR-compliant, no data is used to train AI models. Each project is strictly private and only shared with the people you invite.
Which literature sources are queried?
PubMed and ClinicalTrials.gov by default, with HAL added for French-language literature. References cited in the synopsis link back to their PMID or trial identifier so you can verify them.
What about a rare disease where the literature is sparse?
The AI broadens the search to analogous diseases and treatments to propose a credible rationale. The sample size is then estimated by analogy from similar trials, to be validated with your biostatistician.
Ready to structure your next study?
Create your account, start a conversation with the AI ally, and obtain an exportable bilingual synopsis within hours.